Nussidex

/ Teva

Adults: 1-2 tablets, twice a day, after/with meals.
Children 6-12 Years of Age: 1 tablet once a day ,after/with meals.

Common cold, allergy, rhinitis.

Known hypersensitivity, newborn or premature babies, lactation, asthma or other lower respiratory tract conditions, narrow-angle glaucoma, stenosing peptic ulcer, symptomatic prostatic hypertrophy, bladder neck obstruction, pyloroduodenal obstruction, concomitant use with monoamine oxidase inhibitor therapy.

Safety of use in pregnancy has not been established. The drug should therefore be used during pregnancy only if clearly needed. Drowsiness, history of bronchial asthma, increased intraocular pressure, hyperthyroidism, cardiovascular disease, hypertension.

Drowsiness, lassitude, giddiness, epigastric distress, dryness of mouth, blurred vision, cardiac palpitations, flushing, increased irritability or excitement (especially in children).

Dexchlorpheniramine / Alcohol/CNS Depressants / Sedatives/Hypnotics / Opioid Analgesics / Tricyclic Antidepressants: Concurrent use may potentiate the effects of either these medications or antihistamines. Concomitant administration with tricyclic antidepressants may result in additive antimuscarinic activity
Nussidex/MAO Inhibitors: Concurrent use may prolong and intensify the anticholinergic effects of antihistamines and the effects of sympathomimetics. Severe hypertensive reactions may occur when sympathomimetics are administered to patients receiving MAO inhibitors, or within 14 days of stoping MAO inhibitor treatment. Concomitant use is therefore contraindicated (see Contra-indications).
Antihistamines/Oral Anticoagulants: Action of oral anticoagulants may be decreased by antihistamines.
Pseudoephedrine/β-Blockers: β-Blockers increase the effects of sympathomimetics.
Pseudoephedrine/Methyldopa/Mecamylamine/Reserpine: The antihypertensive effects of these drugs may be reduced by sympathomimetics.
Pseudoephedrine/Inhalation Anesthetics: Administration of pseudoephedrine prior to or shortly after anesthesia may increase the risk of severe ventricular arrhythmias, especially in patients with pre-existing heart disease, because these anesthetics greatly sensitize the myocardium to the effects of sympathomimetics. Therefore caution is recommended in this situation.
Pseudoephedrine/Digitalis glycosides: Concurrent use with pseudoephedrine may increase the risk of cardiac arrhythmias; caution and electrocardiographic monitoring are very important if concurrent use is necessary.
Pseudoephedrine/Levodopa: Concurrent use with pseudoephedrine may increase the possibility of cardiac arrhythmias; dosage reduction of the sympathomimetic is recommended.
Pseudoephedrine/Nitrates: Concurrent use with pseudoephedrine may reduce the antianginal effects of these medications.
Pseudoephedrine/Thyroid Hormones: Concurrent use may increase the effects of either these medications or pseudoephedrine; thyroid hormones enhance risk of coronary insufficiency when sympathomimetic agents are administered to patients with coronary artery disease; therefore dosage adjustment is recommended.
Pseudoephedrine/Sympathomimetics such as Decongestants: Appetite Suppressants and Amphetamine-like Psychostimulants): In addition to possibly increasing CNS stimulation, concurrent use may increase the cardiovascular effects of either the other sympathomimetics or pseudoephedrine.
Pseudoephedrine/Sodium Bicarbonate: Interaction Effect: pseudoephedrine toxicity (agitation, hypertension, tachycardia) may result. The renal elimination of pseudoephedrine is urinary pH and flow dependent. By increasing the urinary pH above 7.5 the renal elimination of pseudoephedrine may decrease by more than 50%. The half-life of pseudoephedrine may be prolonged and an increase in toxicity may be observed.
Pseudoephedrine/Urinary Acidifiers: Urinary acidifiers enhance the elimination of pseudoepehdrine.
Pseudoephedrine/Moclobemide: Risk of hypertensive crisis.
Pseudoephedrine/Ergot Alkaloids (Ergotamine and Methysergide): Increaed risk of ergotism.
Pseudoephedrine/Oxytocin: Risk of hypertension.

Pregnancy: Safety of use in pregnancy has not been established. Caution should be exercised when administered in 1st and 2nd trimesters.
Lactation: Caution should be exercised when administered in breastfeeding.